INSERM U1151, Institut Necker Enfants Malades, Université de Paris, 75015, Paris, France.
Muséum National d'Histoire Naturelle, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université, 75005, Paris, France.
Sci Rep. 2021 Mar 25;11(1):6842. doi: 10.1038/s41598-021-83240-x.
C407 is a compound that corrects the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein carrying the p.Phe508del (F508del) mutation. We investigated the corrector effect of c407 and its derivatives on F508del-CFTR protein. Molecular docking and dynamics simulations combined with site-directed mutagenesis suggested that c407 stabilizes the F508del-Nucleotide Binding Domain 1 (NBD1) during the co-translational folding process by occupying the position of the p.Phe1068 side chain located at the fourth intracellular loop (ICL4). After CFTR domains assembly, c407 occupies the position of the missing p.Phe508 side chain. C407 alone or in combination with the F508del-CFTR corrector VX-809, increased CFTR activity in cell lines but not in primary respiratory cells carrying the F508del mutation. A structure-based approach resulted in the synthesis of an extended c407 analog G1, designed to improve the interaction with ICL4. G1 significantly increased CFTR activity and response to VX-809 in primary nasal cells of F508del homozygous patients. Our data demonstrate that in-silico optimized c407 derivative G1 acts by a mechanism different from the reference VX-809 corrector and provide insights into its possible molecular mode of action. These results pave the way for novel strategies aiming to optimize the flawed ICL4-NBD1 interface.
C407 是一种能校正囊性纤维化跨膜电导调节因子(CFTR)蛋白携带 p.Phe508del(F508del)突变的化合物。我们研究了 C407 及其衍生物对 F508del-CFTR 蛋白的校正作用。分子对接和动力学模拟结合定点突变表明,C407 通过占据位于第四细胞内环(ICL4)的 p.Phe1068 侧链的位置,在共翻译折叠过程中稳定 F508del-Nucleotide Binding Domain 1(NBD1)。在 CFTR 结构域组装后,C407 占据缺失的 p.Phe508 侧链的位置。C407 单独或与 F508del-CFTR 校正剂 VX-809 联合使用,可增加细胞系中的 CFTR 活性,但不能增加携带 F508del 突变的原代呼吸细胞中的 CFTR 活性。基于结构的方法导致合成了一个扩展的 C407 类似物 G1,旨在改善与 ICL4 的相互作用。G1 显著增加了 F508del 纯合患者原代鼻细胞中的 CFTR 活性和对 VX-809 的反应。我们的数据表明,经计算机优化的 C407 衍生物 G1 通过与参考校正剂 VX-809 不同的机制发挥作用,并为其可能的分子作用模式提供了见解。这些结果为旨在优化有缺陷的 ICL4-NBD1 界面的新策略铺平了道路。